About 25 results found for searched term "Raf inhibitor 3" (0.132 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M20688 | B-Raf inhibitor 1 (Compound 13) dihydrochloride | Raf |
| B-Raf inhibitor 1 (Compound 13) is a type IIA Raf inhibitor which bind to the DFG-out conformation with ki of 1 nM,1 nM,and 0.3 nM for B-Raf(WT), B-Raf(V600E) and C-Raf, respectively. | ||
| M42155 | Raf inhibitor 3 | Raf |
| Raf inhibitor 3 is a Raf inhibitor. | ||
| M1761 | Vemurafenib (PLX4032) | Raf |
| RG7204; RO5185426 | ||
| Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy. | ||
| M1774 | PLX-4720 | Raf |
| PLX4720 | ||
| PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively. | ||
| M1827 | Sorafenib Tosylate | VEGFR/PDGFR |
| BAY 43-9006,Nexavar | ||
| Sorafenib (BAY 43-9006) Tosylate is an orally active multikinase inhibitor of tyrosine protein kinases VEGFR/PDGFR and RAF/MEK/ERK with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. | ||
| M2745 | GW5074 | Raf |
| GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. | ||
| M2927 | PF-04880594 | Raf |
| PF-04880594 is a RAF inhibitor for BRAF/BRAFV599E and c-RAF with IC50 of 0.19 nM/0.13 nM and 0.39 nM, >100-fold selectivity over CSNK1, JNK2/3 and p38. | ||
| M3196 | CCT239065 | DNA/RNA Synthesis |
| CCT239065 is a novel and selective BRAFV600E and LCK inhibitor with IC50 of 13 nM and 6 nM, respectively. | ||
| M5005 | Regorafenib Monohydrate | VEGFR/PDGFR |
| BAY 73-4506 monohydrate | ||
| Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. | ||
| M5327 | L-779450 | Raf |
| L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively. | ||
| M5925 | Regorafenib HCl | VEGFR/PDGFR |
| BAY73-4506 hydrochloride | ||
| Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. | ||
| M9492 | B-Raf inhibitor 1 | Raf |
| ABM-0403 | ||
| B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 µM and 2 nM for A375 proliferation and A375 p-ERK, respectively. | ||
| M10475 | Lifirafenib (BGB-283) | Raf |
| Beigene-283 | ||
| Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant. | ||
| M10591 | AZ304 | Raf |
| AZ-304 | ||
| AZ304 is a potent dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF with IC50 values of 79 nM and 38 nM respectively. | ||
| M13561 | C25-140 | TNF Receptor |
| C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity. | ||
| M20609 | CCT196969 | Raf |
| CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs. | ||
| M21513 | Vemurafenib-d7 | Raf |
| PLX4032-d7; RG7204-d7; RO5185426-d7 | ||
| Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy. | ||
| M21520 | Vemurafenib-d5 | Raf |
| Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. | ||
| M27818 | Takeda-6D | Raf |
| Takeda-6D (compound 6d) is an orally active and potent BRAF/VEGFR2 inhibitor, with IC50 values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of ERK1/2 phosphorylation. Takeda-6D shows antitumor activity. | ||
| M27869 | CCT241161 | Raf |
| CCT241161 is an orally active pan-RAF inhibitor with IC50s of 3, 6, 10, 15 and 30 nM for LCK, CRAF, SRC, V600E-BRAF and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity. | ||
| M28168 | HG6-64-1 | Raf |
| HMSL 10017-101-1 | ||
| HG6-64-1 is a potent and selective B-Raf inhibitor, with an IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells. | ||
| M29356 | Raf inhibitor 2 | Raf |
| Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research. | ||
| M30788 | KG5 | Raf |
| KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities. | ||
| M30907 | B-Raf IN 11 | Raf |
| B-Raf IN 11 (ZINC72115182) is a selective B-RafV600E inhibitor (IC50=76 nM), shows selectivity for B-RafV600E over B-RafWT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research[1] | ||
| M42153 | B-Raf IN 13 | Raf |
| B-Raf IN 13 is a BRAF inhibitor with an IC50 of 3.55 nM in BRAF V600E enzyme assay. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
